Postoperative adhesions are abrogated by a sustained-release anti-JUN therapeutic in preclinical models
Authors:
- Deshka S. FosterDFDeshka S. Foster
- Emily MeanyEMEmily Meany
- Charlotte E. BerryCBCharlotte E. Berry
- Mahsa FallahMFMahsa Fallah
- Michael JanuszykMJMichael Januszyk
- Khristian Erich Bauer-RoweKBKhristian Erich Bauer-Rowe
- David M. LopezDLDavid M. Lopez
- Christian M. WilliamsCWChristian M. Williams
- Michelle GriffinMGMichelle Griffin
- 12 March 2025
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (789) , eadp9957
Abstract
Postoperative abdominal adhesions are the leading cause of bowel obstruction and a cause of chronic pain and infertility. Adhesion formation occurs after 50 to 90% of abdominal operations and has no proven preventative or treatment strategy. Abdominal adhesions derive primarily from the visceral peritoneum and are composed of polyclonally proliferating tissue-resident fibroblasts. We have previously shown that signaling of the transcription factor JUN regulates adhesiogenesis and that a small-molecule JUN inhibitor (T-5224) decreases adhesion formation. Here, we encapsulated T-5224 in a shear-thinning hydrogel with antiadhesion properties for intraperitoneal postoperative delivery and sustained release of a JUN inhibitor for adhesion prevention. The material properties of the T-5224–hydrogel support its use for open or minimally invasive surgical application. We found this therapeutic system to be safe, well tolerated, and efficacious in murine and porcine preclinical models. T-5224–hydrogel minimized adhesion quantity and also diminished adhesion fibrosis at an ultrastructural level. Moving toward clinical translation, we developed a large mammal adhesion model in pigs with bowel resection. Single-cell transcriptomic analysis showed that JUN and associated pathway signaling were diminished in adhesion-derived fibroblasts treated with T-5224–hydrogel. The JUN-inhibiting T-5224–hydrogel provided robust prevention of adhesion without deleterious effects on bowel anastomosis or abdominal wall healing. Adhesion biology is similar across surgical sites, and, therefore, this formulation has potential for applicability across the body. The development of therapeutics to prevent adhesions is of paramount importance with potential for high-impact translation to patient care to address a common, unmet clinical need.Keywords
This publication has 48 references indexed in Scilit:
- Injectable Polymer‐Nanoparticle Hydrogel for the Sustained Intravitreal Delivery of BimatoprostAdvanced Therapeutics, 2022
- Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of originCancer Cell, 2022
- Sustained delivery approaches to improving adaptive immune responsesAdvanced Drug Delivery Reviews, 2022
- Modulation of injectable hydrogel properties for slow co‐delivery of influenza subunit vaccine components enhance the potency of humoral immunityJournal of Biomedical Materials Research Part A, 2021
- Prrx1 Fibroblasts Represent a Pro-fibrotic Lineage in the Mouse Ventral DermisCell Reports, 2020
- Low-fat/high-fibre diet prehabilitation improves anastomotic healing via the microbiome: an experimental modelBritish Journal of Surgery, 2020
- Adhesive small bowel obstruction – an updateAcute Medicine & Surgery, 2020
- Trends in open abdominal surgery in the United States—Observations from 9,950,759 discharges using the 2009–2013 National Inpatient Sample (NIS) datasetsThe American Journal of Surgery, 2017
- Large Animal Models: The Key to Translational Discovery in Digestive Disease ResearchCellular and Molecular Gastroenterology and Hepatology, 2016
- A Prospective, Randomized, Multicenter, Controlled Study of the Safety of Seprafilm® Adhesion Barrier in Abdominopelvic Surgery of the IntestineDiseases of the Colon & Rectum, 2003